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Aims To evaluate the prognostic value of quantitative myocardial perfusion imaging with positron emission tomography
(PET) for adverse cardiovascular outcomes in patients with known or suspected coronary artery disease (CAD).
...................................................................................................................................................................................................
Methods
and results
A search in MEDLINE and Embase was conducted for studies that evaluated (i) myocardial perfusion in absolute terms
with PET, (ii) prognostic value for the development of major adverse cardiovascular events (MACE), cardiac death, and/
or all-cause mortality, and (iii) patients with known or suspected CAD. Studies were divided according to the radio-
tracer utilized and their included population (patients with and without previous infarction). Comprehensive description
and a selected instance of pooling were performed. Eight studies (n= 6804) were analysed and documented clear vari-
ability in population, quantitative PET variables operationalization [stress myocardial blood flow (sMBF) and flow reserve
(MFR)], statistical covariate structure, follow-up, and radiotracer utilized. MFR was independently associated with MACE
in eight studies [range of adjusted hazard ratios (HRs): 1.19–2.93]. The pooling instance demonstrated that MFR signifi-
cantly associates with the development of MACEs (HR: 1.92 [1.29, 2.84]; P= 0.001). sMBF was only associated with
MACE in two studies that evaluated it, and only one study documented sMBF as a better predictor than MFR.
...................................................................................................................................................................................................
Conclusion This systematic review demonstrates the prognostic value of quantitative myocardial perfusion evaluated with PET,
in the form of MFR and sMBF, for the development of major adverse cardiovascular outcomes in populations with
known or suspected CAD. In the qualitative comparison, MFR seems to outperform sMBF as an independent prog-
nostic factor. Evidence is still lacking for assessing quantitative PET for the occurrence of cardiac death and all-
cause mortality. There is clear heterogeneity in predictor operationalization and study performances.
                                                                                                                                                                                                                   
Keywords quantitative positron emission tomography • myocardial perfusion • myocardial blood flow • myocardial flow
reserve • coronary artery disease • prognostic value • cardiovascular events
* Corresponding author. Tel: þ316 5128 9545; Fax: þ35822318191. E-mail: l.e.juarez.orozco@gmail.com
VC The Author(s) 2017. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
European Heart Journal - Cardiovascular Imaging (2017) 00, 1–9
doi:10.1093/ehjci/jex331
Downloaded from https://academic.oup.com/ehjcimaging/advance-article-abstract/doi/10.1093/ehjci/jex331/4780290
by The University of Edinburgh user
on 20 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Introduction
Non-invasive imaging has rapidly developed to offer assessment of
coronary atherosclerosis and myocardial ischaemia with tools such
as computed tomography (CT), single photon emission tomography
(SPECT), echocardiography, magnetic resonance (MR), and positron
emission tomography (PET). Recently, the diagnostic capacities of
these techniques have been compared, showing that the PET per-
forms best in the detection of obstructive coronary artery disease
(CAD).1
Traditionally, PET and SPECT have evaluated cardiac perfusion de-
fects through a standardized 5-point semi-quantitative analysis. Yet,
the greatest advantage of PET myocardial perfusion imaging lies in its
capability to fully quantify myocardial blood flow (MBF) in absolute
terms (i.e. mL/g/min), which has proved to be superior to relative up-
take evaluation.2 MBF is measured during rest (rMBF) and stress
(sMBF), which is achieved through pharmacological vasodilatory
hyperaemia. With this measurements, the sMBF/rMBF ratio can be
calculated, which is known as the coronary perfusion reserve, myo-
cardial perfusion reserve, coronary flow reserve, or myocardial flow
reserve (MFR).3 Both MFR and sMBF have demonstrated utility in the
identification of significant CAD and performance superiority of the
latter over the former has been suggested.4
Recently, a number of publications have explored the added prog-
nostic value that full quantitative PET perfusion can offer.5,6
However, this data has not yet been systematically analysed,7 and
sources of heterogeneity are suspected. Moreover, whether MFR or
sMBF might be better suited for prognostic evaluation is still
uncertain.
Hence, the purpose of this systematic review and meta-analysis is
to evaluate the available literature and investigate the prognostic
value of absolute MFR and sMBF quantification with PET for the oc-
currence of major adverse cardiovascular events (MACE) and death
in patients with known or suspected CAD. Additionally, we describe
how the value of MFR and sMBF compares to each other in the cur-
rently available publications.
Methods
This review was conducted in accordance to the PRISMA statement
and registered in the International Prospective Register of Systematic
Reviews (PROSPERO2016: CRD42016033938).
Information sources and search
A search in electronic databases was conducted including MEDLINE and
Embase for studies published in English language until August 2017. The
search terms included MeSH and free-words to identify relevant records.
The complete search can be consulted in the Supplementary data online,
Table S1.
Study screening and selection
Two independent reviewers (L.J., R.S.) screened the search results to
identify studies suited for full-text evaluation using the following criteria:
The studies should (i) have evaluated MFR and/or sMBF in absolute terms
with PET, (ii) have evaluated its prognostic value for MACE, cardiac death,
and/or all-cause mortality, and (iii) have been conducted in patients
studied for CAD (known or suspected)-related ischaemia. Reviews,
editorials, abstracts, animal studies, conference presentations, or studies
on diagnostic performance were excluded. Studies conducted in patients
with hypertrophic cardiomyopathies or heart transplantation were not
included.
Data extraction and quality assessment
Data extraction was conducted according to the following subheadings:
study characteristics, population description, predictor measurement (i.e.
detailed description of the technique employed), index test (i.e. MFR and
sMBF measurement and operationalization) and outcome measure
(events description), and quantitative results (multivariate modelling and
estimators). Data on the (comparative) performance of both quantitative
perfusion estimates (MFR and sMBF) were also extracted when available.
Discrepancies or uncertainties were resolved by consensus (R.T.). If study
data were used in multiple publications (i.e. articles that referred a similar
number of patients or from the same inclusion period and the same med-
ical centre evaluated through the same imaging protocol), only the results
from that with the largest number of patients in the quantitative analysis
were included.
We utilized the modified Quality in Prognostic Studies (QUIPS) ap-
praisal tool considering study participation, attrition, prognostic factor
measurement, outcome measurement, confounding account, and statis-
tical analysis.8 First, the risk of bias was determined for each domain (as
low, unclear, or high-risk). Then, the overall risk for each study was
judged. Study quality was not considered restrictive for inclusion, but it
was comprehensively evaluated.
Index predictors’ summary measures and
outcome evaluation
We evaluated the hazard ratios (HRs) and accompanying 95% confidence
intervals (CIs) and P-values reported for the index predictors (MFR and
sMBF) from the multivariate survival analyses reported in the included
studies. Particularly, we obtained first the independent HRs of MFR, and
then, the independent HRs of sMBF (if present) when accounting for
MFR in the reported models in order to evaluate the comparative prog-
nostic value of both perfusion estimates. The HR ranges were described
for the outcomes of interest as follows: First, we examined the develop-
ment of MACE. We documented the combination of endpoints that con-
stituted the definition of MACE as established by the authors of every
original paper9 including events such as: cardiac death, MI, acute coronary
syndromes, percutaneous transluminal coronary angioplasty, CABG,
heart failure, stroke, and peripheral vascular disease. Then, we analysed
the occurrence of cardiac death alone. This included only those studies
that specifically reported a HR for the specific outcome. Finally, we
analysed the reported development of all-cause mortality by grouping re-
ports documenting such event category.
There are no current criteria established for the evaluation of prog-
nostic variables in systematic reviews. Nevertheless, we considered that
both the MFR and sMBF fulfilled a recently proposed criterion as an inde-
pendent prognostic factor (i.e. evaluated in at least three independent
studies with an included summed total of >1000 patients).10
Based on clinical relevance, we highlighted the division of included
studies according to the utilized perfusion tracer (13N-ammonia, 82Rb, or
15O-water) and the predominance of patients with previous myocardial
infarction (MI).
Due to expected variation in MFR and sMBF handling and statistical
covariate structure, we only calculated a selected pooled HR for the occur-
rence of any of the outcomes (MACE, cardiac death, and all-cause mortal-
ity) if the following conditions were met: (i) the studies were conducted in
a similar population (either with or without a majority of patients with pre-
vious MI), (ii) the studies utilized the same cut-off value for or the same
2 L.E. Jua´rez-Orozco et al.
Downloaded from https://academic.oup.com/ehjcimaging/advance-article-abstract/doi/10.1093/ehjci/jex331/4780290
by The University of Edinburgh user
on 20 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..operationalization of the index predictor, and (iii) the studies performed a
survival analysis that did not raise a concern for ‘overfitting’ (i.e. that the
number of covariates in the model did not exceed a ratio of 1 predictor
per 10 outcome events). A random-effects model was used to pool the
HRs, and the inverse variance method, using the log HR and its standard
error, was used to assign the weights. The amount of variance between the
studies was estimated using the DerSimonian and Laird method.11
Statistical heterogeneity between included studies was assessed using
the I2 statistic.12 Statistical significance was set at P< 0.05. Analyses were
performed using SPSS v.21, R, and RevMan 5.
Results
Search results and study selection
The results of the database search and study selection process are
summarized in Figure 1. Our search identified 3196 potentially rele-
vant studies. Twenty-five full-text articles were reviewed from which
17 studies were eligible, and eight were ultimately included in the
quantitative description and analysis13–20 (see Supplementary data
online, Table S2 for individual study characteristics).
Two publications studied a population with a majority of subjects
with evidence of a previous MI and were performed with 13N-ammo-
nia,13,17 while six others studied mainly subject without previous MI,
three using 82Rb,15,16,18 one using 13N-ammonia,14 one using 82Rb
and 13N-ammonia,20 and one using 15O-water.19
Only four studies evaluated the prognostic value of sMBF and
described its comparison to MFR (three using 82Rb16,18,20 and one using
15O-water19). Figure 2 depicts the areas of commonality between the
included studies for this and other relevant aspects discussed ahead.
Characteristics and methodological
aspects of the studies
The setting and population were clearly described in the included
studies providing a summed total of 6804 patients. Five studies
included mostly patients without a previous MI,14,16,18–20 which rep-
resent an interesting target population highlighted in current guide-
line recommendations on the role of PET myocardial perfusion
imaging (i.e. patients with an intermediate pre-test likelihood of
CAD). Sample characteristics and prevalence of risk factors are
shown in Table 1.
Gupta et al.20 provided the largest sample with 4029 included pa-
tients who underwent PET imaging (86% of patients in this study
were imaged using 82Rb and 14% with 13N-ammonia). Conversely,
no single study with 13N-ammonia has included a comparable sample.
Notably, the second study in sample size ranking (Ziadi et al.15)
included roughly six times less patients. Virtually all studies included
predominantly male patients, except for Fukushima et al.16 (38%) and
Gupta et al.20 (50%).
The most severe clinical profile of patients was included in the
studies by Tio et al.13 and Slart et al.,17 which precisely constitute the
studies with a majority of patients with a previous MI (71 and 81%, re-
spectively). Although these two studies were performed in the same
centre in the Netherlands, the reported samples were independent
from each other (the former considering patients without and the lat-
ter with PET-driven revascularization). Beyond the operational separ-
ation made between studies with patients with or without a majority
of previous MI, there were differences in the demographic character-
istics and CV risk profile of the populations recruited. Regarding age,
the described and included studies were generally conducted in
Figure 1 study flow chart.
A prognostic systematic review on quantitative PET myocardial perfusion imaging 3
Downloaded from https://academic.oup.com/ehjcimaging/advance-article-abstract/doi/10.1093/ehjci/jex331/4780290
by The University of Edinburgh user
on 20 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..middle aged and elderly patients with moderate spread in the range
of means (58–67 years of age). Further, arterial hypertension, Type 2
diabetes mellitus, dyslipidaemia, and smoking habit varied importantly
between studies.
Three radiotracers were described for the assessment of myocar-
dial perfusion with consequent differences in the implemented kinetic
models, stressor agents, analysis, and corrections made for the rest-
ing cardiac work index [rate-pressure product (RPP)] (technical de-
tails of the selected studies are shown in Supplementary data online,
Table S3).
The follow-up average range was 12–117 months for the analysis
of MACE development, 66–88 months for the analysis of cardiac
death, and 43–117 months for the analysis of all-cause mortality. The
study by Gupta et al.20 had the longest follow-up (117 months).
The publication by Maaniitty et al.19 was the only study on
the prognostic value of quantitative cardiac PET using 15O-water.
Interestingly, it focused on the value of sMBF alone. Conversely, the
studies by Farhad, Fukushima, and more recently, Gupta addressed
the comparative value of MFR and sMBF with alternating results (see
Discussion).
Although all the included studies reported performing a multivari-
ate stepwise proportional hazard (Cox) regression that incorporated
MFR, sMBF or both in the last step of the analysis, issues were found
concerning the operationalization index predictors and model con-
struction (as described recently by El Aidi et al.10). The analysis char-
acteristics as well as number of events and reported pooled HRs, for
MACE, cardiac death, and all-cause mortality are shown in Table 2.
Four studies dichotomized MFR or sMBF according to a particular
cut-off point either derived from literature or the variable distribu-
tion in their sample. Two of these described the same cut-off value
(<2.0): one performed with 82Rb15 and the other with 13N-ammo-
nia.14 The third study made use of a different cut-off (<2.11) and uti-
lized 82Rb,16 while the fourth19 considered a cut-off of <_2.4 only for
sMBF. With regard to the other included studies, two operationalized
MFR per unit decrease, one using 82Rb18 and the other, 13N-ammo-
nia.17 Only, Tio et al.13 handled MFR as predictor per standard devi-
ation decrease (see Figure 2 for a schematic depiction of these
differences).
Another heterogeneity source was found in the amount of covari-
ates included in the reported multivariate analysis across studies,
Figure 2 common methodological features of included studies.
....................................................................................................................................................................................................................
Table 1 Demographic descriptive statistics of the included studies
Study Perfusion
tracer
Number of
patients
Men (%) Age
(SD or IQR)
HTN (%) DM (%) Dyslip. (%) Previous
MI (%)
Previous
Revasc.
Tio et al.13 Ammonia 344 78.8 66 (11) 29 13 57 71 74
Herzog et al.14 Ammonia 229 69.0 60 (12) 60 18 59 0 53
Ziadi et al.15 82Rb 677 61.4 64 (12) 68 29 69 40 45
Fukushima et al.16 82Rb 224 38.4 58 (13) 63 34 45 12 0
Slart et al.17 Ammonia 119 80.7 67 (11) 35 15 45 81 81
Farhad et al.18 82Rb 318 63.5 65 (10) 65 34 56 20 0
Maaniitty et al.19 15O-H2O 864 56.5 64 (9) 67 20 70 0 0
Gupta et al.20 82Rb/Ammonia 4029 49.5 66 (18) 83 36 68 28 36
DM, diabetes mellitus; Dyslip, dyslipidaemia; HTN, arterial hypertension; IQR, interquartile range; MI, myocardial infarction; N/R, not reported; Revasc, revascularization;
SD, standard deviation.
4 L.E. Jua´rez-Orozco et al.
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.which ranged from 2 in Fukushima et al.16 to 16 in Gupta et al.20 (for
a complete depiction of the covariate structure and variable selec-
tion methods see Supplementary data online, Table S4). Importantly,
in a relevant proportion of the included studies (4 of 8) the num-
ber of events per variable included in the multivariable survival
analysis was <10, which may have led to an overestimation of the
reported HRs due to ‘overfitting’.21 From these, two were
performed with 13N-ammonia,14,17 one with 82Rb,18 and one with
15O-water.19
Risk of bias within studies
Figure 3 summarizes the risk of bias assessment using the QUIPS tool.
The risk of bias was considered low overall. The only domain that
showed a sustained uncertain risk of bias was the ‘prognostic factor
measurement’ due to the differences in population characteristics
and tracer utilized (see Supplementary data online, Figure S5 for the
individual evaluation of the studies).
Prognostic value of quantitative PET
for MACE
All eight studies analysed and reported HRs for the development of
MACE [seven studies analysed MFR (5940 patients) and four analysed
sMBF (4973 patients)]. The types of included events are shown in
Table 2 (a total of 878 events were documented), and a comprehen-
sive view of reported estimates is presented in Figure 4.
MFR demonstrated to be an independent predictor in each of the
involved studies, with multivariable HRs ranging between 1.19 and
2.93. Only the lower CI described by Herzog et al.14 reached but did
not cross the null effect boundary. The studies performed with 13N-
ammonia reported lower HRs with narrower CIs than the ones per-
formed with 82Rb (mean HR: 1.41 vs. 2.41, respectively). Among
these 13N-ammonia studies, Tio et al.13 and Slart et al.17 included a
majority of patients with previous MI, while Herzog et al.14 still re-
ported 53% of this prevalence.
Conversely, sMBF only proved to be a significant predictor in two
of four studies (HRs = 2.44–3.62) (see Figure 4 upper right panel). In
the other two, Gupta et al.20 documented a non-significant HR for
sMBF (1.03), while Fukushima et al.16 did not report the correspond-
ing HR (yet disclosed as inferior and no longer significant when com-
pared with MFR).
The only viable statistical pooling (as specified by the criteria men-
tioned under Methods) was performed for MFR with the studies by
Herzog et al.14 and Ziadi et al.15 given that both included a similar
population (without previous MI), both utilized the same cut-off value
for MFR (<2.0) and neither raised a concern for statistical ‘overfitting’.
This meta-analysis showed that a reduced MFR associated signifi-
cantly with the occurrence of MACEs (pooled-HR = 1.92 [1.29–
2.84]; P= 0.001) with evidence of minimal statistical heterogeneity
(I2 = 19%).
P
P
P
P
Figure 4 summary of multivariate HRs. The colors correspond to the tracer utilized in the study (see Figure 2).
Figure 3 risk of bias.
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Prognostic value of quantitative PET for
cardiac death
Three studies13,14,17 (all using 13N-ammonia) analysed and reported
HRs occurrence of cardiac death (692 patients) with 111 events
documented. However, according to the cited criteria for evaluating
an independent prognostic factor,10 there was not enough evidence
in order to establish the prognostic value of MFR, while sMBF was
not evaluated for this outcome. Still, the multivariable HRs ranged be-
tween 1.27 and 4.11. The HR reported in the study by Slart et al.,17
performed with 13N-ammonia in patients with previous MI, greatly
diverged from the other three studies considered (see Figure 4 middle
left panel), one of which was the study performed in the same centre
by Tio et al.13 On the other hand, Herzog et al.14 documented consid-
erably wider CIs than Tio et al.13 and Slart et al.17 Both the studies by
Slart et al.17 and Herzog et al.14 raised concern for ‘overfitting’. As
such, there was no viable statistical pooling to be performed as con-
sidered by our criteria.
Prognostic value of quantitative PET for
all-cause mortality
Only two included studies (one performed with 82Rb and 13N-am-
monia in a 9:1 ratio20 and one with 15O-water19) estimated HRs for
the development of all-cause mortality (4893 patients with 1023
events). Once more, according to the criteria for prognostic factor
evaluation, there was not enough evidence in order to establish the
prognostic value of MFR or sMBF for this outcome (<3 studies).
Interestingly, despite the large sample size analysed by Gupta et al.,20
the multivariable HR reported for MFR was statistically significant
(1.72), while the one documented for sMBF was not (see Figure 4 in-
ferior panels). Additionally, Maaniitty et al.19 directly reported a non-
significant HR for sMBF.
Qualitative prognostic performance of
MFR vs. sMBF
Overall, from the three included studies that compared the prognos-
tic significance of MFR to that of sMBF, Fukushima et al.16 and Gupta
et al.20 reported a better independent performance of MFR, and only
Farhad et al.18 documented a marginally better performance of sMBF.
Discussion
This systematic review has confirmed that quantitative myocardial
perfusion as evaluated by PET MFR is recurrently associated with an
increased risk of MACE in individual studies, while consistent evi-
dence of the prognostic value of sMBF is currently insufficient.
Interestingly, the degree to which MFR reflects this risk was found
to be substantially heterogeneous across different patient popula-
tions. Furthermore, we documented relevant sources of variability in
the methodological aspects of the papers involved, namely: the oper-
ationalization of the index predictors (MFR and sMBF), the covariate
structure of the survival models reported (ranging from 2 to 16 cova-
riates), and the follow-up times and the radiotracer utilized (82Rb,
13N-ammonia, and 15O-water). Because of these factors, full pooling
of the reported HRs was not performed as it would generate virtually
uninterpretable estimates.
Notably, we found great inconsistencies in MFR and sMBF opera-
tionalization as well as in the covariate structures utilized in the re-
ported Cox models. This is explained by the prevalent lack of
standardization in the statistical approach to evaluate the prognostic
value of potential useful variables. Also, at the time some of the stud-
ies were performed, reports supporting particular diagnostic cut-off
values were emerging. Still, prognostic cut-off values are generally
constructed in a different fashion, according to the observed risk of
events. Along this thread of thought, some reports have suggested
MFR has ‘incremental’ value over left ventricular ejection fraction
(LVEF) (four studies included LVEF as a covariate), which constitutes
a powerful predictor of risk in patients with CAD. Interestingly, two
of the studies included described some measure of incremental value
based on the ‘net reclassification index’ (Ziadi et al.15 and Gupta
et al.20). Still, reclassification evaluation was not widely applied in the
studies included. Hence, our review could not categorically estimate
the effect of the improvement in predictive performance. We would
like to encourage application of novel reclassification metrics in the
future.
When distinction was made between studies that included a ma-
jority of patients with previous MI, and arguably, a more severe clin-
ical profile, it was shown that the HRs for the occurrence of MACE
were lower than the ones in studies that analysed patients without
previous MI (a clinical profile more commonly referred to PET imag-
ing in diagnostic practice). It would seem, consequently, that the
prognostic value of MFR is lower for high-risk populations.
There was a notable discrepancy between the reported HRs in
Slart et al.17 and Tio et al.13 for the occurrence of cardiac death but
not for the development of MACE. These two studies were per-
formed in the same institution and using the same radiotracer.
However, the first studied a population that did, and the second, that
did not undergo PET-driven revascularization. Additionally, MFR
operationalization was different between both studies. This could
suggest that the principal influence of revascularization procedures
per se is an improvement in the long-term risk of cardiac death rather
than in other cardiovascular events. Further research in particular
outcomes commonly clustered into the concept of MACE is, there-
fore, warranted.
The results of the single instance in which pooling of the reported
HRs was conducted (shown in Figure 5) demonstrated a MFR < 2.0
roughly translates a two-fold increase in the risk of developing
MACE. This result is to be considered with caution because although
the two studies involved (Herzog et al.14 and Ziadi et al.15) met the
requirements to minimize methodological heterogeneity, they were
performed with a different tracer. On the other hand, we believe it is
likely that this pooled estimate may represent an adequate approxi-
mation to the ‘real’ overall HR, and it would be of interest to explore
its validation through further clinical research.
Another main insight emerging from these results is the clear pau-
city and inconsistency of evidence regarding the prognostic role and
performance of sMBF. Recent data have suggested that sMBF has a
better diagnostic performance than MFR for the detection of signifi-
cant CAD, and it has been suspected that sMBF may consequently
convey a better prognostic value. In the present systematic review,
four studies considered sMBF in their analyses16,18–20 and three of
these16,18,20 compared it directly to MFR. From these studies, only
Farhad et al.18 reported that the comparison favoured sMBF as a
A prognostic systematic review on quantitative PET myocardial perfusion imaging 7
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stronger independent prognostic factor. Interestingly, in the large
scale comparison performed by Gupta et al.,20 MFR but not sMBF
proved to be a significant predictor for the risk of all-cause mortality.
On the other hand, the study by Maaniitty et al.19 only assessed sMBF
due to the implemented protocol in their centre (sequential CT and
stress PET). Yet, their study also demonstrated that even with very
wide CIs, sMBF was only a significant predictor of MACE and not of
all-cause mortality. Albeit sMBF can be obtained in rapid stress-only
protocols, and it may overcome difficulties posed by groups of pa-
tients with a higher resting flow (which can artificially hamper MFR),
these results suggest that MFR may convey a more robust prognostic
value than sMBF. As such,
sMBF may be more suitable only in CAD diagnosis when there is
no evidence of a previous infarction. As such, sMBF may be more
suitable only in CAD diagnosis when there is no evidence of a pre-
vious infarction.
The clinical role of quantitative PET perfusion imaging has been al-
ready established based on its ability to provide accurate diagnosis of
myocardial ischaemia in patients ranging from subclinical disease to
overt symptomatic and worsening clinical pictures, with an improved
performance over relative perfusion analysis. PET-measured MFR
can be used to assess the ischaemic burden of atherosclerotic lesions
in CAD and microvascular dysfunction. At the same time, MFR can
provide a notion of the inherent risk associated with the status of the
vasodilatory capacity of the coronary tree. This implies that PET-
measured MFR could provide a target for the evaluation of emerging
therapies that might modify patients’ short- and long-term risk profile.
To present date, selected publications have only suggested its poten-
tial role in the improvement of risk stratification.
Reduction in MFR and sMBF may arise either from flow-limiting
atherosclerotic lesions in epicardial coronary arteries or from
vasodilatory dysfunction of small-calibre arterioles in the myocar-
dium (because of hampering in endothelial reactivity). A clear link
has been established between obstructive coronary stenosis and
an increased risk of MI, although recent studies suggest that plaque
characteristics and disease activity are also likely to play a role.22
In addition, small vessel disease closely relates to the presence of
comorbidities (such as Type 2 diabetes mellitus and hypertension)
which can also alter resting MBF and MFR. These comorbidities
are themselves associated with an increased risk for progressive
myocardial dysfunction and other adverse events. The combin-
ation of both these factors is therefore likely to account for the
elevated risk for both fatal and non-fatal adverse outcomes associ-
ated with reductions in MFR and possibly sMBF. Still, our results
support the notion that MFR is better suited for evaluating disease
and risk characterization.
This report represents the first comprehensive systematic review
characterizing the prognostic significance of MFR and sMBF. Due to
constrains of the data and emerging criteria for the standardized
evaluation of prognostic factors in biomedical sciences,10 we deter-
mined that quantitative myocardial perfusion with PET constitutes a
statistically proven independent predictor for the risk of MACE and
that there is currently not enough evidence in order to establish its
prognostic value for cardiac death and all-cause mortality. A particu-
lar mention of the study by Gupta et al. should be made since it pro-
vided the largest sample (4029) and the longest follow-up recorded.
However, the considered criteria for evaluating prognostic factors
propose that evidence is insufficient when the variable has been
tested in a cumulative sample of <1000 patients and/or <3 studies.
This case probably constitutes a grey area in prognostic systematic
reviews as we believe that their estimates should be reasonably con-
sidered as they factor strongly into the available evidence.
There were also clear technical differences documented. Although
such factors may pose sources of variation in the estimates of MFR
and sMBF, the reproducibility of PET quantitative perfusion has been
shown to be considered good to excellent when the kinetic models
for perfusion quantification estimation are equal.23 Importantly, we
underline the necessity for further standardization at every level of
analysis, which was recently highlighted in published PET guidelines.24
Although the reported analysis varied greatly, quality of the studies
was overall good. This supports further analysis on individual patient
data. As proposed elsewhere for cardiac MR,25 a PET registry would
be an optimal approach to overcome complication inherent to
report-based analyses.
Finally, our results may encourage practitioners to assume a more
active position regarding tailored patient treatment. We believe our
report could support a shift in the interest deposited in PET-derived
quantitative perfusion measurements from considering them only as
relevant markers of risk to potentially utilizing them as relevant trial
endpoints. Finally, individual outcome specific research into the effi-
cacy for risk modification and cost–benefit analyses may represent
the best guide to develop PET quantitative myocardial perfusion
regular clinical use.
Conclusion
This systematic review demonstrates the prognostic value of
quantitative myocardial perfusion evaluated with PET, in the form
Figure 5 forest plot. Predictor-MFR, outcome-MACE. The colors correspond to the tracer utilized in the study (see Figure 2).
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of MFR and sMBF, for the development of major adverse cardio-
vascular outcomes in populations with known or suspected CAD.
In the qualitative comparison, MFR seems to outperform sMBF as
an independent prognostic factor. Evidence is still lacking for eval-
uating the prognostic value of quantitative PET for the occurrence
of cardiac death and all-cause mortality. There is clear heterogen-
eity in predictor operationalization and study performances and
underlines the need for further standardization to maximize the
clinical benefit of the technique.
Supplementary data
Supplementary data are available at European Journal of Echocardiography
online.
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